ITGA2 and chronic myelogenous leukemia, BCR-ABL1 positive: The analysis showed that ITGA2 gene expression was significantly upregulated in CML patients, with the highest levels observed in the AP (p < 0.05) and BC (p < 0.01) phases compared to the healthy group (Figure 7A).